v3.25.1
Total revenues - Revenue by collaboration and by category of revenue (Details) - EUR (€)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Disclosure of disaggregation of revenue from contracts with customers [line items]      
Total collaboration revenues € 240,786,000 € 239,724,000 € 241,249,000
Total net revenues 275,649,000 239,724,000 241,249,000
Gilead      
Disclosure of disaggregation of revenue from contracts with customers [line items]      
Royalties 10,604,000 9,466,000 10,726,000
Gilead collaboration agreement for drug discovery platform      
Disclosure of disaggregation of revenue from contracts with customers [line items]      
Total collaboration revenues 230,182,000 230,242,000 230,423,000
Recognition of non-refundable upfront payments and license fees 230,200,000    
Novartis collaboration agreement for MOR106      
Disclosure of disaggregation of revenue from contracts with customers [line items]      
Total collaboration revenues     56,000
Royalties [Member]      
Disclosure of disaggregation of revenue from contracts with customers [line items]      
Total collaboration revenues 10,604,000 9,482,000 10,770,000
Gilead royalties on Jyseleca      
Disclosure of disaggregation of revenue from contracts with customers [line items]      
Total collaboration revenues 10,604,000 9,466,000 10,726,000
Gilead royalties on Jyseleca | Gilead      
Disclosure of disaggregation of revenue from contracts with customers [line items]      
Royalties € 10,600,000    
Other royalties      
Disclosure of disaggregation of revenue from contracts with customers [line items]      
Total collaboration revenues   € 16,000 € 44,000